Skip to content
Acceleron Pharma

Investors/Media

Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Jun 23, 2017
Results from ongoing study demonstrate increases in hemoglobin and decreases in red blood cell transfusion burden sustained for up to 24 months, with patients still active on treatment CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutica...
Jun 23, 2017
- Results from ongoing trials demonstrate increases in hemoglobin and reductions in red blood cell transfusion burden sustained for more than 26 months - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on th...
Jun 12, 2017
- DART Phase 2 study of dalantercept plus axitinib did not achieve its primary endpoint - - Acceleron to discontinue development of dalantercept - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focu...
Jun 1, 2017
- Companies expect to report top-line results from the Phase 3 studies in mid-2018 - SUMMIT, N.J. & CAMBRIDGE, Ma.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that they have completed target enrollment in the MEDALIS...
Jun 1, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that senior management will participate in two upcoming ...
May 18, 2017
- Presentations to highlight efficacy, duration of response, and long-term safety results from ongoing Phase 2 studies with luspatercept in myelodysplastic syndromes and beta-thalassemia - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceut...
May 8, 2017
- Luspatercept MEDALIST and BELIEVE Phase 3 trials expected to complete enrollment in Q2 2017 - - Presented results from ongoing Phase 2 trial with luspatercept at the 14th International Symposium on MDS - - Announced plans to initiate luspatercept Phase 3 trial in first-l...
May 6, 2017
- Preliminary results show that treatment with investigational drug luspatercept achieves meaningful erythroid response rates and transfusion independence in first-line, lower-risk myelodysplastic syndromes patients - - Celgene and Acceleron plan to initiate a Phase 3 trial in first-line,...
May 2, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ: XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that Steven Ertel, due to medical reasons, will transition...
May 1, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that senior management will participate in two upcoming ...
Apr 27, 2017
- Enrollment in MEDALIST and BELIEVE Phase 3 studies now expected to be completed in Q2 2017 - - Acceleron and Celgene to initiate an additional Phase 3 trial in first-line, lower-risk MDS in early 2018 to expand opportunity beyond ongoing MEDALIST study - CAMBRIDGE,...
Apr 26, 2017
- Management to review highlights from luspatercept clinical presentations at the 14th International MDS Symposium - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commerci...
Apr 6, 2017
Oral presentation highlights new Phase 2 data in additional sub-populations of lower-risk MDS CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative...
Mar 16, 2017
- Second Phase 2 study for ACE-083 expected to begin 2H 2017 - - Company to host educational webinar with leading clinical researcher on April 3rd at 11:00 a.m. EDT - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical ...
Mar 1, 2017
- Luspatercept Phase 3 trials to complete enrollment in both the MDS ("MEDALIST") and beta-thalassemia ("BELIEVE") trials in 2H 2017 - - Presented data from five abstracts on luspatercept and sotatercept at the American Society of Hematology Annual Meeting in December - - Treated f...
Page:
...
Next Last
 
= add release to Briefcase